Xin Lang Cai Jing·2025-09-07 07:43Core Viewpoint - Junshi Biosciences announced positive results from the Phase III clinical study of its humanized anti-IL-17A monoclonal antibody JS005 for the treatment of moderate to severe plaque psoriasis [1] Group 1: Clinical Study Results - The study was led by Professor Zhang Jianzhong from Peking University People's Hospital and conducted across 60 research centers nationwide [1] - The primary objective was to achieve at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) and a static Physician's Global Assessment (sPGA) score of 0 or 1 at week 12, comparing JS005 to a placebo [1] - Results indicated that JS005 significantly improved psoriasis lesions and severity compared to the placebo, with a higher proportion of participants achieving an sPGA score of 0 or 1 [1] Group 2: Safety and Regulatory Plans - The safety profile of JS005 was found to be good among participants with moderate to severe plaque psoriasis [1] - The company plans to submit a marketing authorization application for the product to regulatory authorities in the near future [1]